|
Comparison of results after subgrouping horses due to clinical and light microscopic findings |
|||||||
| n |
Histological score: median (span) |
IHC (MP): median (span) |
IHC (PII): median (span) |
IHC (BE): median (span) |
IHC (percentage): median (span) |
PCR: positive cases (percentage) |
|
|
|
|||||||
| Subgroup I |
15 |
0 (0–2) |
0 (0–1) |
0 (–-4) |
6 (–-63) |
0.359 (0–4,79) |
5 (33.3) |
| Subgroup II |
5 |
5 (4–6) |
0 (0–1) |
0 (0–2) |
76 (11–119) |
4.853 (0.88–8.92) |
4 (80) |
| Subgroup III |
16 |
1 (0–5) |
0 (0–1) |
0 (0–2) |
81.5 (4–474) |
6.065 (0.20–25.4) |
13 (81.2) |
| Subgroup IV |
9 |
22 (12–29) |
1 (0–4) |
22 (0–63) |
246 (20–535) |
21.024 (1.37–37.1) |
2 (22.2) |
| Mann-Whitney-U *exact Fisher test |
I vs. II: p < 0.001 I vs. III: p = 0.033 I vs. IV: p < 0.001 II vs. III: p = 0.003 II vs. IV: p = 0.001 III vs. IV: p < 0.001 |
I vs. II: p = n. s. I vs. III: p = n. s. I vs. IV: p = 0.041 II vs. III: p = n. s. II vs. IV: p = n. s. III vs. IV: p = 0.037 |
I vs. II: p = n. s. I vs. III: p = n. s. I vs. IV: p < 0.001 II vs. III: p = n. s. II vs. IV: p = 0.007 III vs. IV: p < 0.001 |
I vs. II: p = 0.033 I vs. III: p < 0.001 I vs. IV: p < 0.001 II vs. III: p = n. s. II vs. IV: p = 0.042 III vs. IV: p = 0.023 |
I vs. II: p = 0.015 I vs. III: p < 0.001 I vs. IV: p < 0.001 II vs. III: p = n. s. II vs. IV: p = 0.042 III vs. IV: p = 0.020 |
I vs. II: p = n. s.* I vs. III: p = 0.019* I vs. IV: p = n. s.* II vs. III: p = n. s.* II vs. IV: p = n. s.* III vs. IV: p = 0.009* |
|
|
Subgroup I: Clinically healthy horses without histological changes of RAO Subgroup II: Clinically healthy horses with a low inflammation score of 4–6 Subgroup III: Horses with clinical signs of RAO, but without or only slight histological changes and a score of 0–5 Subgroup IV: Horses with symptoms and histological changes of RAO with a score > 10 IHC: Number of CP antigen-positive cells in 3 high power fields MP: macrophages, PII: type II pneumocytes, BE: bronchiolar epithelial cells IHC (percentage): number of all CP antigen-positive cells in 3 high power fields in relation to all cells | |||||||
Theegarten et al. Respiratory Research 2008 9:14 doi:10.1186/1465-9921-9-14 |
|||||||